Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

20022,949 citationsJournal Article

Authors

Charles L. Vogel · Sylvester Comprehensive Cancer Center

Abstract

Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Topics & Keywords

HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 3, pp. 719-726

DOI: 10.1200/jco.20.3.719

Field-Weighted Citation Impact: 66.35